Spruce Biosciences Sees Growth After Harbour BioMet Investment, Stock Surges 43%
Spruce Biosciences, a Nasdaq‑listed biotech focused on endocrinology and orphan drugs, sees a boost from Harbour BioMet’s stake amid volatile stock swings.
2 minutes to read